FinanceCity
HealthcareNSE · BSE

Anthem Biosciences Limited

ANTHEM · ISIN INE0CZ201020

Share price

₹773 -0.12%

Market capitalisation

₹43392 CrClosed

Live from Yahoo Finance. Pulse animates during NSE market hours (9:15–15:30 IST, weekdays).

01 · Key metrics

Market cap

₹43392 Cr

Current price

₹773

-0.12% today

52W high

₹874

52W low

₹579

Stock P/E

73.99

P/B ratio

14.25

02 · Per share & returns

EPS (TTM)

₹10.44

Book value

₹54.19

ROE

21.71%

ROA

14.02%

Dividend yield

0.26%

Beta

03 · Financials (TTM)

By the numbers

Revenue

₹2124 Cr

+26.40% YoY

EBITDA

₹834 Cr

Net profit

₹592 Cr

+127.20% YoY

Profit margin

27.86%

Operating margin

37.26%

Total debt

₹53.92 Cr

Total cash

₹939 Cr

Debt / equity

0.02x

Current ratio

5.54x

Payout ratio

0.00%

04 · Analyst view

Target price

₹879

Upside

+13.84%

Consensus

STRONG BUY

Analysts

7

05 · Shareholding pattern

Who owns ANTHEM?

  • Promoters

    74.68%

    Founders & promoter group

  • Institutions

    10.83%

    FII + DII

  • Public

    14.49%

    Retail & non-institutional

As of 31 Mar 2026 · Source: NSE corporate filings

06 · Registration & listing

On the record

Symbol
ANTHEM
Exchange
NSE · BSE
CIN
ISIN
INE0CZ201020
BSE code
544449
Sector
Healthcare
Industry
Healthcare
Face value
₹2
Listing date
20 Jul 2025
Employees
Headquarters
Bengaluru, India

07 · About

What is Anthem Biosciences Limited?

Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the concept stage; preclinical development; and manufacturing development batches of molecules used for clinical Phase I, II, and III trials up to commercial manufacturing of RNA-based therapies, antibody-drug conjugates, peptides and oligonucleotides, lipids, biologics and biotherapeutics, fermentation, biosynthesis and biotransformation, and flow chemistry. It also manufactures and sells complex specialized fermentation-based active pharmaceutical ingredients (APIs), including serratiopeptidase protease and vitamin K2; microbial and mammalian biosimilars; probiotics, such as bacillus species, lactobacillus species, bifidobacterium species, streptococcus species and saccharomyces boulardii; enzymes; peptides, including semaglutide, plecanatide, linaclotide, liraglutide, and cilengitide; nutritional actives, vitamin analogues, and APIs. The company was incorporated in 2006 and is based in Bengaluru, India.

08 · Common questions

Frequently asked

What is the CIN of Anthem Biosciences Limited?+

The Corporate Identity Number for Anthem Biosciences Limited is published in the MCA21 corporate master. FinanceCity backfills CIN values during weekly refreshes.

Who are the promoters of Anthem Biosciences Limited?+

Promoter holding in ANTHEM is approximately 74.68%, as disclosed in the latest published shareholding pattern.

What is the market capitalisation of Anthem Biosciences Limited?+

Anthem Biosciences Limited (ANTHEM) has a market capitalisation of approximately ₹43392 Cr, reflecting the most recent weekly refresh from the BSE scrip master.

09 · Adjacent

Other healthcare listings

Full sector →